Novo Nordisk, the company behind the popular weight-loss drug Wegovy, is facing serious consequences for concealing payments.
They failed to properly report millions of pounds in funding to various UK healthcare organizations over many years.
This lack of transparency, along with subsequent failures after an internal review, led to a formal reprimand from regulators.
The incident highlights serious concerns about the pharmaceutical industry's ethical standards and calls for increased accountability.
